Clinical Trials Browser

Phase 1/2 × Recruiting × Daunorubicin × Clear all

NCT07008638 2025-07-09

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute